Incyte
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study of Ruxolitinib in Pancreatic Cancer Patients
Phase 3
Terminated
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 86
- Registration Number
- NCT02119663
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- NSCLC (Non-small Cell Lung Carcinoma)
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 76
- Registration Number
- NCT02119650
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Phase 3
Terminated
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 321
- Registration Number
- NCT02117479
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
Phase 1
Terminated
- Conditions
- MDS (Myelodysplastic Syndrome)
- Interventions
- Drug: INCB047986
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT02093429
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Phase 1
Completed
- Conditions
- B-Cell Malignancies
- Interventions
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 88
- Registration Number
- NCT02018861
- Locations
- 🇺🇸
Greenville Health System Cancer Institute, Greenville, South Carolina, United States
🇺🇸Nyu Langone Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Phase 1
Terminated
- Conditions
- Metastatic CancerHodgkin's LymphomaPancreatic CancerBreast CancerUC (Ureter and Urethera)Solid TumorNHL (Non-Hodgkin Lymphoma)Advanced Cancer
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT01929941
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Phase 1
Active, not recruiting
- Conditions
- B-cell Malignancies
- Interventions
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 121
- Registration Number
- NCT01905813
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Pancreatic CancerSolid Tumors
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 55
- Registration Number
- NCT01858883
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Solid TumorsPancreatic Cancer
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT01822756
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
Phase 2
Terminated
- Conditions
- Genitourinary (GU) TumorsOvarian Cancer
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT01685255
© Copyright 2025. All Rights Reserved by MedPath